百令胶囊联合优甲乐治疗自身免疫性甲状腺炎疗效分析

Efficacy analysis of Bailing capsule combined with Euthyrox in treatment of autoimmune thyroiditis

目的探究百令胶囊联合优甲乐治疗自身免疫性甲状腺炎的临床疗效。方法选取128例自身免疫性甲状腺炎患者,随机分为观察组(64例)与对照组(64例)。对照组口服优甲乐治疗,观察组口服百令胶囊+优甲乐治疗,对比两组临床疗效和甲状腺功能变化。结果治疗前两组促甲状腺素(TSH)、血清游离三碘甲腺原氨酸(FT3)及游离甲状腺素(FT4)与抗甲状腺过氧化物酶抗体(TPO Ab)及甲状腺球蛋白抗体(TG Ab)比较均无显著性差异(P>0.05);连续用药3个月后,两组FT3、FT4水平较治疗前显著升高(P<0.05),而TSH、TPO Ab及TG Ab水平较治疗前显著降低(P<0.05)。观察组总有效率和显效率(68.75%、26.56%)均显著高于对照组(45.32%、10.94%)(P<0.05);两组不良反应发生率比较无显著差异(P>0.05)。结论百令胶囊联合优甲乐治疗自身免疫性甲状腺炎可显著改善甲状腺功能,提高治疗效果,可作为首选辅助治疗手段应用于临床。

Objective To explore the clinical efficacy of Bailing capsule combined with Euthyrox in the treatment of autoimmune thyroiditis. MeAods A total of 128 patients with autoimmune thyroiditis were randomly divided into an observation group and a control group （n =64, respectively）. The control group was treated with Euthyrox orally, and the observation group wastreated with Bailing capsule plus Euthyrox orally. The clinical efficacy and thyroid function were compared between the tw-o groups. Results Before the treatment, there were no significant differences between the t＊wo groups in thyroid-stimulating hormone （TSH）, serum free triiodothyronine （FT3） and free thyroxine （FT4）, thyroid peroxidase antibody （TPO Ab） and thyroid globulin antibody （TG Ab）. After three months of treatment, the levels of FT3 and FT4 in the two groups were significantly higher than those before the treatment （P 〈 0.05）, while TSH, TPO Ab and TG Ab levels were significantly lower than those before the treatment （P 〈 0.05）. The total effective rate and effective rate （68.75% and 26.56%） of the observation group were significantly higher than those in the control group （45.32% and 10.94%） （P 〈 0.05）, and there was no significant difference in the incidence of adverse reactions between the tw-ogroups （P 〉 0.05）. Conclusion Bailing capsule combined with Euthyrox in the treatment of autoimmune thyroiditis can significantly improve the thyroid function and improve the clinical efficacy. It can be used as the first choice for clinical treatment.